Jump to content

Peritoneal Mesothelioma: Difference between revisions

From WikiMesothelioma — Mesothelioma Knowledge Base
← Older edit
MesotheliomaSupport (talk | contribs)
Bots, Bureaucrats, Administrators
2,015 edits
VisualWikitext
Fix 3 broken references: SEER 404→CDC stats, Yan PMID 19273710→19917862, Helm PMID 25391263→25124472
Add links to related pages: Heated Chemotherapy (HITHOC and HIPEC), Palliative Care for Mesothelioma, Mesothelioma Nutrition and Supportive Care, Gene Therapy
 
(10 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{#seo:
{{#seo:
|title=Peritoneal Mesothelioma: CRS/HIPEC Outcomes, 41-59% 5-Year Survival & Treatment Advances
|title=Peritoneal Mesothelioma: Symptoms, Treatment & Survival
|description=Comprehensive guide to peritoneal mesothelioma — diagnosis, CRS/HIPEC treatment, PCI scoring, survival data, emerging therapies, and legal compensation options for patients and families.
|description=Comprehensive guide to peritoneal mesothelioma — the second most common mesothelioma type. Covers HIPEC treatment achieving 53-month median survival, diagnosis, legal rights, and compensation options.
|keywords=peritoneal mesothelioma, peritoneal mesothelioma treatment, CRS HIPEC, peritoneal cancer index, peritoneal mesothelioma survival, peritoneal mesothelioma prognosis, PIPAC, immunotherapy mesothelioma
|keywords=peritoneal mesothelioma, malignant peritoneal mesothelioma, HIPEC, cytoreductive surgery, abdominal mesothelioma, peritoneal mesothelioma treatment, peritoneal mesothelioma survival, asbestos peritoneum
|image=peritoneal-mesothelioma-treatment.jpg
|author=WikiMesothelioma Editorial Team
|author=Rod De Llano, Founding Partner, Danziger & De Llano
|published_time=2026-03-13
|published_time=2026-02-06
}}
}}


{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
{| class="wikitable" style="float:right; margin:0 0 1em 1em; width:300px;"
! colspan="2" style="background:#1a5276; color:white; text-align:center;" | Peritoneal Mesothelioma
|-
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Peritoneal Mesothelioma
| '''Also Known As''' || Malignant Peritoneal Mesothelioma (MPM)
|-
|-
| colspan="2" style="padding:10px; text-align:center; font-style:italic;" | Critical facts for diagnosis and treatment
| '''Location''' || Peritoneum (abdominal lining)
|-
|-
| style="padding:10px; font-weight:bold; width:40%;" | % of All Cases
| '''Annual US Cases''' || ~800 new cases per year
| style="padding:10px;" | '''10–20%'''
|-
|-
| style="padding:10px; font-weight:bold;" | Gender Ratio
| '''Percentage of Meso''' || 7–30% of all mesothelioma
| style="padding:10px;" | '''1.2:1 (M:F)'''
|-
|-
| style="padding:10px; font-weight:bold;" | CRS/HIPEC 5-Yr OS
| '''Median Survival (HIPEC)''' || ~53 months
| style="padding:10px;" | '''41–59%'''
|-
|-
| style="padding:10px; font-weight:bold;" | Chemo-Only Median
| '''5-Year Survival''' || 30–50% with optimal treatment
| style="padding:10px;" | '''~12 months'''
|-
|-
| style="padding:10px; font-weight:bold;" | PCI Scoring Range
| '''Peak Latency''' || 20–50 years
| style="padding:10px;" | '''0–39'''
|-
| style="padding:10px; font-weight:bold;" | BAP1 Mutations
| style="padding:10px;" | '''38–45%'''
|-
| style="padding:10px; font-weight:bold;" | Women 5-Yr OS
| style="padding:10px;" | '''68% vs 39% men'''
|-
| style="padding:10px; font-weight:bold;" | Median Age
| style="padding:10px;" | '''50–65 years'''
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | <span data-nosnippet class="noai-content">[https://www.mesotheliomalawyercenter.org/asbestos/ '''Free Case Review →''']</span>
|}
 
= Peritoneal Mesothelioma: Treatment Advances, Survival Data, and Emerging Therapies =
 
== Executive Summary ==
 
Malignant peritoneal mesothelioma (MPM) represents the second most common site of mesothelioma, accounting for 10–20% of all mesothelioma diagnoses in the United States, with approximately 315–800 new cases diagnosed annually.<ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref><ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases | Mesothelioma Lawyer Center]</ref> Unlike pleural mesothelioma, which predominantly affects men with occupational asbestos exposure, peritoneal mesothelioma demonstrates a near-equal gender distribution (1.2:1 male-to-female ratio), with approximately 20–40% of cases occurring without documented asbestos exposure—a distinction that reflects higher rates of secondary/paraoccupational exposure and germline genetic factors such as BAP1 mutations.<ref name="dandellperitoneal">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs. Peritoneal Mesothelioma: Key Differences | Danziger & De Llano]</ref> Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care for eligible patients, extending median overall survival from approximately 12 months with chemotherapy alone to 34–92 months in selected cohorts, with 5-year survival rates of 41–59%.<ref name="pmcyan">[https://pubmed.ncbi.nlm.nih.gov/19917862/ Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. ''J Clin Oncol.'' 2009;27(36):6237-6242.]</ref><ref name="pmchelm">[https://pubmed.ncbi.nlm.nih.gov/25124472/ Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. ''Ann Surg Oncol.'' 2015;22(5):1686-1693.]</ref><ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma | Mesothelioma.net]</ref> Notably, women experience superior outcomes compared to men—68% five-year survival versus 39% in men—an advantage attributed to younger age at diagnosis, better performance status, and potential hormonal protective factors.<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide | Danziger & De Llano]</ref> Emerging therapies including pressurized intraperitoneal aerosol chemotherapy (PIPAC) for palliative care and downstaging, immunotherapy with checkpoint inhibitors, and targeted approaches addressing BAP1 mutations (present in 38–45% of cases) are expanding treatment options beyond traditional CRS/HIPEC for unresectable and relapsed disease. The peritoneal cancer index (PCI) scoring system, which stratifies disease burden on a 0–39 scale, remains the most important prognostic indicator—patients with PCI ≤20 achieve five-year survival rates exceeding 50%, while those with PCI ≥30 experience dramatically reduced survival.
 
== Key Facts ==
 
{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Peritoneal Mesothelioma
|-
| style="padding:15px;" |
* '''Disease Burden:''' 10–20% of all mesothelioma cases; approximately 315–800 new cases annually in the United States<ref name="seermeso" />
* '''Near-Equal Gender Distribution:''' 1.2:1 male-to-female ratio, dramatically different from pleural mesothelioma (1:7)
* '''Asbestos Attribution:''' 60–80% of cases have documented asbestos exposure; 20–40% occur without identifiable exposure
* '''Standard Treatment:''' CRS/HIPEC achieves 5-year survival of 41–59%, compared to ~12 months with chemotherapy alone<ref name="pmcyan" /><ref name="pmchelm" />
* '''Peritoneal Cancer Index (PCI):''' Divides abdomen into 13 regions on 0–39 scale; PCI ≤20 predicts 5-year OS >50%<ref name="pmchelm" />
* '''Gender-Based Outcomes:''' Women achieve 68% 5-year survival vs. 39% in men after CRS/HIPEC
* '''BAP1 Mutations:''' Present in 38–45% of peritoneal mesothelioma cases; associated with more inflamed tumor microenvironment<ref name="pmcbap1">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436227/ Ladanyi M. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. ''Genome Med.'' 2019;11(1):18.]</ref>
* '''Emerging PIPAC Therapy:''' Minimally invasive pressurized aerosol chemotherapy enables downstaging of unresectable disease
* '''Immunotherapy Data:''' Growing evidence of checkpoint inhibitor activity in unresectable peritoneal mesothelioma
* '''Misdiagnosis Risk:''' Frequently misdiagnosed as ovarian cancer in women due to overlapping presentation and imaging findings
|}
|}


== What Is Peritoneal Mesothelioma? ==
= Peritoneal Mesothelioma =
 
Peritoneal mesothelioma is a rare, aggressive cancer arising from the mesothelial cells that line the peritoneum—the serosal membrane of the abdominal cavity.<ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Malignant Mesothelioma Treatment (PDQ) – Patient Version, National Cancer Institute]</ref><ref name="mlccancer">[https://www.mesotheliomalawyercenter.org/asbestos/cancer/ Asbestos Cancer | Mesothelioma Lawyer Center]</ref> It is the second most common site of mesothelioma development after the pleura (lung lining). The disease typically presents with non-specific abdominal symptoms including pain, distension, ascites (fluid accumulation), and weight loss, often resulting in delayed diagnosis by 4–6 months from initial symptom presentation.
 
The peritoneum is a thin, slippery membrane that lines the abdominal and pelvic cavities, providing a protective barrier around organs and allowing them to move freely. When asbestos fibers reach the peritoneum and become lodged in this lining, they trigger chronic inflammation and malignant transformation of mesothelial cells. The disease remains largely confined to the abdominal cavity, distinguishing it from pleural mesothelioma, which can metastasize to distant sites. Unlike pleural mesothelioma's male predominance, peritoneal mesothelioma occurs with nearly equal frequency in men and women—a distinction with significant clinical and legal implications.
 
== What Causes Peritoneal Mesothelioma? ==
 
=== Asbestos Exposure Pathways ===
 
Asbestos is the primary known risk factor for peritoneal mesothelioma, though the pathways by which inhaled or ingested fibers reach the peritoneum are incompletely understood. The most widely accepted mechanism involves '''mucociliary clearance and gastrointestinal translocation''': inhaled asbestos fibers trapped in the respiratory tract are cleared upward by the mucociliary escalator, swallowed, and enter the gastrointestinal tract, where they may penetrate the intestinal wall and lodge in the mesentery or peritoneal cavity.<ref name="mlcasbestos">[https://www.mesotheliomalawyercenter.org/asbestos/ Asbestos Exposure Information | Mesothelioma Lawyer Center]</ref> Alternative mechanisms include direct translocation through diaphragmatic lymphatics and hematogenous or lymphatic spread.
 
Once lodged in the peritoneum, asbestos fibers irritate mesothelial cells, causing chronic inflammation, chromosomal instability, and eventually malignant transformation. Both amphibole fibers (crocidolite, amosite) and chrysotile demonstrate association with peritoneal mesothelioma development. Cumulative exposure thresholds vary by fiber type: >16.4 f/cc-years for crocidolite, 23.6 f/cc-years for amosite, and higher thresholds for chrysotile variants.
 
=== Secondary and Paraoccupational Exposure ===
 
A distinctive feature of peritoneal mesothelioma—particularly in women—is that secondary (paraoccupational) exposure is responsible for a significant proportion of cases. This includes:
 
* Laundering contaminated work clothing
* Direct physical contact with asbestos-exposed family members
* Exposure to contaminated household dust and environments
* Residential proximity to asbestos-using industries
 
Lung fiber burden analysis demonstrates that women with paraoccupational exposure accumulated fiber concentrations comparable to men with moderate direct occupational exposure, explaining the higher proportion of peritoneal mesothelioma in women relative to pleural disease. This has major implications for legal causation arguments.
 
=== Non-Asbestos Risk Factors ===
 
Approximately 20–40% of peritoneal mesothelioma cases occur '''without documented asbestos exposure'''. Contributing factors include:
 
* '''BAP1 mutations (38–45% somatic, ~12% germline):''' BRCA1-Associated Protein 1 mutations significantly increase mesothelioma susceptibility, sometimes with dramatically shortened latency periods (as brief as 8 years). Germline BAP1 mutation carriers can develop mesothelioma with minimal or absent asbestos exposure.<ref name="pmcbap1" />
* '''Prior abdominal radiation:''' Documented as an independent risk factor
* '''Chronic peritoneal inflammation:''' Conditions like Mediterranean familial fever and chronic peritonitis increase risk
* '''Genetic predisposition:''' Beyond BAP1, germline BRCA mutations have been described in select cases
 
== What Are the Symptoms of Peritoneal Mesothelioma? ==
 
Peritoneal mesothelioma presents with non-specific abdominal symptoms that frequently delay diagnosis by months. Common presenting symptoms include:


* Abdominal pain and distension/bloating (>30–50% of cases)
Malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer arising from the mesothelial cells lining the peritoneum — the membrane surrounding the abdominal cavity and organs.<ref name="pmc4754312" /> It is the second most common form of mesothelioma after pleural mesothelioma, accounting for approximately 7–30% of all diagnoses.<ref name="pmc5674249" /> Approximately 800 new cases are diagnosed in the United States each year.<ref name="pmc4754312" />
* Ascites (fluid accumulation in abdomen)—often the presenting finding
* Weight loss and early satiety (feeling full quickly)
* Nausea, vomiting, and bowel obstruction
* Fatigue and decreased energy
* Palpable abdominal mass (occasional)
* Fever and temperature fluctuations
* New-onset hernia


The non-specific nature of these symptoms and the rarity of the disease contribute to significant diagnostic delay. Median time from initial presentation to diagnosis is typically '''4–6 months'''.<ref name="ncimeso" /><ref name="dandellcauses">[https://dandell.com/asbestos-exposure/mesothelioma-symptoms-causes-legal-options/ Mesothelioma: Symptoms, Causes & Legal Options | Danziger & De Llano]</ref>
Unlike pleural mesothelioma, peritoneal mesothelioma has a near-equal male-to-female ratio and a meaningful proportion of cases (20–40%) occur in patients without documented asbestos exposure.<ref name="pmc5674249" /> The disease has been transformed by the development of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), which has extended median survival from approximately 12 months to 53 months or more in selected patients.<ref name="yan2009" />


=== The Ovarian Cancer Misdiagnosis Problem ===
== Overview ==


A particularly important diagnostic challenge is that peritoneal mesothelioma in women is frequently '''misdiagnosed as ovarian cancer or primary peritoneal carcinoma''' due to overlapping clinical presentation (ascites, omental caking, elevated CA-125) and similar radiographic appearance. Documented cases exist where women's peritoneal mesothelioma was initially assumed to be ovarian cancer, with the correct diagnosis only established during surgery or on final pathology review. This misdiagnosis can delay appropriate multimodality treatment and affects legal causation narratives. Immunohistochemistry demonstrating mesothelial markers (calretinin+, CK5/6+, WT-1+) and absence of adenocarcinoma markers (BerEP4−) is critical for distinguishing these entities.
=== Definition and Incidence ===


== How Is Peritoneal Mesothelioma Diagnosed? ==
Peritoneal mesothelioma develops in the peritoneum, the serosal membrane lining the abdominal cavity and covering the abdominal organs.<ref name="pmc4754312" /> The disease remains rare, with an age-adjusted incidence rate of approximately 1.02 cases per 1,000,000 person-years in the United States based on SEER data from 2000–2018.<ref name="pmc9818958" /> US incidence has remained broadly stable over that period, though unadjusted case counts increased by 64.9% driven primarily by new diagnoses in women.<ref name="pmc9818958" />


=== Imaging and Cross-Sectional Evaluation ===
=== Demographics ===


Diagnosis begins with clinical suspicion based on diffuse abdominal symptoms and/or ascites. '''CT imaging is the first-line diagnostic modality''', revealing diffuse omental masses, mesenteric nodules, peritoneal thickening, and ascites.<ref name="ncimeso" /><ref name="mlcexposure">[https://www.mesotheliomalawyercenter.org/asbestos/exposure/ Asbestos Exposure Risks | Mesothelioma Lawyer Center]</ref> Favorable CT findings (ascites with minimal soft tissue disease and preserved small bowel anatomy) predict better outcomes and increased likelihood of complete cytoreduction. Unfavorable findings include absent ascites with large diffuse nodular thickening and marked bowel distortion.
Peritoneal mesothelioma differs meaningfully from pleural mesothelioma in patient demographics:


MRI with specialized diffusion-weighted imaging protocols can accurately predict peritoneal cancer index (PCI) preoperatively. PET/CT shows FDG uptake along the peritoneum and in regional lymph nodes but remains of unclear initial diagnostic value. Enteral contrast is recommended to delineate small bowel involvement.
* '''Male-to-female ratio''': Approximately 1.2:1 — dramatically more balanced than pleural mesothelioma's 4:1 male predominance<ref name="pmc9818958" />
* '''Median age at diagnosis''': 50–65 years<ref name="pmc4754312" /><ref name="pmc9818958" />
* '''Race/ethnicity''': White patients account for approximately 75% of cases in SEER data<ref name="pmc9818958" />
* '''Female representation in surgical series''': Some CRS/HIPEC centers report that women comprise 59% of operated patients<ref name="pmc4754312" />


=== Diagnostic Biopsy ===
Women with peritoneal mesothelioma consistently demonstrate superior outcomes after treatment, with 5-year survival rates of 68% in women versus 39% in men.<ref name="pmc5674249" />


'''Diagnostic laparoscopy has become the preferred approach''' for obtaining tissue, offering the added advantages of:
=== Asbestos Attribution ===
* Direct visualization of tumor burden and distribution
* Assessment of peritoneal cancer index
* Identification of patients eligible for CRS/HIPEC
* Avoidance of unnecessary exploratory laparotomy in unresectable cases


Paracentesis (fluid aspiration) has '''limited diagnostic utility''' because malignant cells are typically sparse in ascites. However, fine-needle aspiration of peritoneal tumor implants combined with immunohistochemistry can establish diagnosis.
Asbestos is the primary known cause of peritoneal mesothelioma, but the attribution rate is lower than for pleural disease. Approximately 60–80% of peritoneal mesothelioma cases have documented asbestos exposure, meaning 20–40% of patients have no identifiable occupational or environmental asbestos contact.<ref name="pmc5674249" /> By contrast, approximately 96% of pleural mesothelioma cases are attributable to asbestos.<ref name="dandell1" /> The weaker attribution in peritoneal cases reflects a higher proportion of female patients with secondary (paraoccupational) exposure, a greater role for BAP1 germline mutations, and incomplete occupational histories.


=== Immunohistochemistry Confirmation ===
== Symptoms and Diagnosis ==


Definitive diagnosis requires a panel of immunohistochemical antibodies:
=== Symptom Profile ===


'''Mesothelial markers (positive in mesothelioma):'''
Peritoneal mesothelioma presents with non-specific abdominal symptoms that frequently delay diagnosis by a median of 4–6 months from initial presentation.<ref name="pmc5674249" /> The most common presenting symptoms include:
* Calretinin (most sensitive)
* Cytokeratin 5/6 (CK5/6)
* WT-1 (Wilms Tumor-1)
* D2-40 (podoplanin)
* HBME-1
* Vimentin


'''Adenocarcinoma markers (negative—used to exclude ovarian/GI cancers):'''
* '''Abdominal distension and bloating''' — occurring in over 30–50% of patients<ref name="pmc5674249" />
* BerEP4
* '''Abdominal pain''' — occurring in over 30–50% of patients<ref name="pmc5674249" />
* CEA
* '''Ascites''' (fluid accumulation) — often the presenting clinical finding<ref name="pmc4754312" />
* B72.3
* '''Weight loss''' and early satiety<ref name="pmc4754312" />
* MOC-31
* '''Nausea, fatigue''', and altered bowel habits<ref name="mesnet1" />
* TTF-1
* '''New-onset hernia''' or palpable abdominal mass (less common)<ref name="pmc5674249" />


Two or more mesothelial markers confirm diagnosis. Loss of BAP1 nuclear expression is highly specific for distinguishing mesothelioma from benign mesothelial proliferation. Loss of MTAP expression serves as a surrogate for CDKN2A deletion and supports malignancy.
Due to these non-specific symptoms, peritoneal mesothelioma is frequently misdiagnosed as ovarian cancer in women, irritable bowel syndrome, or peritoneal carcinomatosis from other primary cancers such as stomach, pancreas, or colon.<ref name="pmc5674249" />


=== Serum Biomarkers ===
=== Key Facts: Peritoneal Mesothelioma at a Glance ===


Biomarkers assist in diagnosis and prognosis:
{| class="wikitable" style="width:100%; border:2px solid #1a5276;"
* '''Mesothelin:''' Elevated in up to 71% of cases with 84.6% sensitivity
! style="background:#1a5276; color:white;" | Fact
* '''CA-125:''' Elevated in 53% of cases; more useful for monitoring recurrence
! style="background:#1a5276; color:white;" | Data
* '''CA 15-3:''' Elevated in approximately 48.5% of cases
* '''Osteopontin:''' Shows promise as complementary biomarker
 
== What Is CRS/HIPEC and Why Is It the Standard Treatment? ==
 
=== Procedure Overview and Technical Details ===
 
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is the '''established standard of care''' for selected peritoneal mesothelioma patients. The procedure occurs in two distinct phases:
 
'''Phase 1: Cytoreductive Surgery (CRS):''' Complete macroscopic tumor removal through peritonectomies (removal of affected peritoneal surfaces) and visceral resections. A complete parietal peritonectomy removes all peritoneum regardless of gross appearance, because microscopic disease may involve 54% of normal-appearing peritoneum. Visceral resections may include partial or total gastrectomy, colectomy, small bowel resection, splenectomy, or gynecologic organ resection depending on extent of disease. The goal is CC-0 or CC-1 cytoreduction (no residual disease or <2.5 mm residual).
 
'''Phase 2: Hyperthermic Intraperitoneal Chemotherapy (HIPEC):''' After complete resection, heated chemotherapy is circulated directly within the abdominal cavity at 41–42°C for 60–90 minutes to address microscopic residual disease. The abdominal cavity is temporarily closed with a temporary plastic barrier (Redon technique), heated saline is circulated, and chemotherapy is delivered. Cisplatin-based regimens (cisplatin alone or cisplatin + doxorubicin) are preferred, as cisplatin-based HIPEC is associated with superior survival compared to mitomycin C protocols. The entire procedure typically lasts 6–10 hours.
 
=== Patient Selection Criteria ===
 
Not all patients are candidates for CRS/HIPEC. Selection criteria include:
 
* '''Peritoneal Cancer Index (PCI) ≤20:''' Generally favorable for complete cytoreduction; PCI 21–30 is moderate; PCI >30 indicates high-burden disease with significantly worse outcomes
* '''Performance Status:''' Adequate physiological health to tolerate a major abdominal operation (ECOG 0–2 preferred)
* '''Cell Type:''' Epithelioid histology preferred; sarcomatoid and biphasic subtypes have worse outcomes and require careful patient selection
* '''CT Imaging Criteria:''' Absence of >5 cm tumor in epigastric region and preserved small bowel/mesentery anatomy predict 94% probability of complete cytoreduction
* '''Absence of Extra-Abdominal Disease:''' Peritoneal mesothelioma rarely metastasizes distantly, making distant disease a relative contraindication
 
=== Completeness of Cytoreduction (CC) Scoring ===
 
The completeness of cytoreduction is the strongest independent predictor of survival:
 
{| class="wikitable" style="width:100%; margin:1em 0;"
|-
|-
! style="background:#1a5276; color:white; padding:10px;" | CC Score
| Annual US cases || ~800 new diagnoses per year
! style="background:#1a5276; color:white; padding:10px;" | Definition
! style="background:#1a5276; color:white; padding:10px;" | Prognosis
|-
|-
| CC-0 || No residual disease || Best outcomes
| Share of all mesothelioma || 7–30% (most cited: 10–20%)
|-
|-
| CC-1 || Residual tumor <2.5 mm || Good outcomes
| Male-to-female ratio || ~1.2:1 (near-equal)
|-
|-
| CC-2 || Residual tumor 2.5 mm – 2.5 cm || Significantly worse
| Cases with no asbestos exposure || 20–40%
|-
|-
| CC-3 || Residual tumor >2.5 cm || Poorest outcomes
| Median age at diagnosis || 62–65 years
|}
 
Complete cytoreduction (CC-0 or CC-1) is achieved in approximately '''67% of patients''' undergoing CRS/HIPEC and is the most consistent independent predictor of improved survival across all major studies.
 
=== CRS/HIPEC Survival Data by Study ===
 
{| class="wikitable" style="width:100%; margin:1em 0;"
|-
|-
! style="background:#1a5276; color:white; padding:10px;" | Study
| Latency period || 20–50 years from first exposure
! style="background:#1a5276; color:white; padding:10px;" | Year
! style="background:#1a5276; color:white; padding:10px;" | Patients
! style="background:#1a5276; color:white; padding:10px;" | Median OS
! style="background:#1a5276; color:white; padding:10px;" | 5-Year OS
|-
|-
| Yan et al. (multi-institutional)<ref name="pmcyan" /> || 2009 || 401 || 53 months || 47%
| Median survival (untreated) || ~6 months
|-
|-
| Alexander et al. (3 US centers) || 2013 || 211 || 38.4 months || 41%
| Median survival (chemo alone) || ~12 months
|-
|-
| Feldman et al. (NCI)<ref name="ncimeso" /> || 2003 || 49 || 92 months || 59%
| Median survival (CRS/HIPEC) || ~53 months
|-
|-
| Baratti et al. (Milan) || 2013 || 108 || 63.2 months || 52.4%
| 5-year survival (CRS/HIPEC) || 41–59%
|-
|-
| Sugarbaker (CRS+HIPEC+NIPEC) || 2022 || 35 || Not reported || ~80%
| Trust fund compensation range || $7,000–$1.2 million per fund
|-
|-
| Helm et al. (meta-analysis)<ref name="pmchelm" /> || 2015 || 1,047 || — || 42%
| Average lawsuit settlement || $1 million–$1.4 million
|}
|}


CRS/HIPEC extends median survival to '''34–92 months''' depending on patient selection, compared to approximately '''12 months with chemotherapy alone''' and '''6 months without treatment'''.<ref name="ncimeso" /><ref name="mesonetchemo">[https://mesothelioma.net/mesothelioma-chemotherapy/ Mesothelioma Chemotherapy | Mesothelioma.net]</ref>
=== Diagnostic Imaging ===


=== Treatment Centers of Excellence ===
CT scan of the chest, abdomen, and pelvis is the initial imaging modality of choice.<ref name="pmc4754312" /> Favorable CT findings include ascites with minimal soft-tissue masses and preserved bowel architecture. Unfavorable CT findings include large nodular thickening with marked bowel distortion, which predicts incomplete cytoreduction.<ref name="pmc4754312" />


Major referral centers specializing in peritoneal mesothelioma include:
MRI with diffusion-weighted imaging can predict the peritoneal cancer index (PCI) preoperatively with good accuracy.<ref name="pmc4754312" /> FDG-PET/CT demonstrates uptake along the peritoneum but has unclear utility for initial staging.<ref name="pmc11652017" />


* '''Washington Cancer Institute / Paul Sugarbaker:''' Pioneer of CRS/HIPEC; reported ~80% 5-year survival with CRS+HIPEC+NIPEC approach
=== Tissue Biopsy and Immunohistochemistry ===
* '''National Cancer Institute (NCI):''' Feldman et al. reported 92-month median survival in selected patients<ref name="ncimeso" />
* '''MD Anderson Cancer Center:''' Major referral for peritoneal surface malignancies<ref name="ncimeso" />
* '''Moffitt Cancer Center:''' Active in treatment and clinical trials
* '''National Cancer Institute Milan (Deraco/Baratti):''' Published outcomes in 108–116 patients with 49–52.4% 5-year survival
* '''University of Pittsburgh:''' Prognostic factor analysis and multimodality treatment


{| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
Diagnostic laparoscopy with biopsy is the preferred approach to obtain tissue, as it allows simultaneous visualization of tumor burden and PCI assessment.<ref name="pmc5674249" /><ref name="pmc4754312" /> Paracentesis and cytology of ascitic fluid has limited diagnostic yield and is not recommended as a sole approach.<ref name="pmc5674249" />
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "CRS/HIPEC represents the most significant advance in peritoneal mesothelioma treatment in decades. We have seen patients who were told they had months to live survive for 10, 15, even 20 years with aggressive surgery and heated chemotherapy followed by systemic therapy and careful surveillance."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
|}


== How Does Cell Type Affect Treatment and Survival? ==
A panel of immunohistochemical markers is required to confirm diagnosis. Positive mesothelial markers include calretinin, cytokeratin 5/6, WT-1, and D2-40. Negative markers used to exclude adenocarcinoma include BerEP4, CEA, and TTF-1.<ref name="pmc5674249" /> Loss of BAP1 nuclear expression is highly specific for distinguishing malignant from benign mesothelial proliferation.<ref name="pmc5674249" />


=== Epithelioid Peritoneal Mesothelioma ===
=== Peritoneal Cancer Index (PCI) Scoring ===


Epithelioid is the '''most common subtype''', comprising 79–91% of surgical cases. This cell type carries the '''best prognosis''':
The Peritoneal Cancer Index (PCI) is the standard tool for quantifying disease burden, dividing the abdomen into 13 regions and assigning each a lesion-size score of 0–3. The maximum PCI score is 39.<ref name="pmc4754312" /> PCI correlates directly with prognosis and surgical eligibility:


* Median age-standardized survival: 16.6 months in population-based data
* '''PCI 1–10''' (Stage I): 5-year overall survival 87%<ref name="pmc4754312" />
* Epithelioid histology is an independent predictor of improved survival in CRS/HIPEC patients on multivariate analysis
* '''PCI 11–20''' (Stage II): 5-year overall survival 53%<ref name="pmc4754312" />
* Preferred for aggressive surgical intervention
* '''PCI ≤19''': Associated with improved overall survival (p = 0.001)<ref name="nature2020" />
* In surgical series with CRS/HIPEC, epithelioid patients achieve median survivals of 50–60 months
* '''PCI ≥30''': Associated with significantly worse survival (p = 0.002)<ref name="nature2020" />


=== Sarcomatoid Peritoneal Mesothelioma ===
== Treatment Options ==


Sarcomatoid is the '''rarest and most aggressive''' subtype, representing only 1–9.5% of surgical cases:
Peritoneal mesothelioma treatment has advanced substantially over the past two decades. The current standard of care for eligible patients combines cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). For patients who cannot undergo surgery, systemic chemotherapy and emerging immunotherapy approaches are available. For information on related options, see [[Treatment_Options|treatment options]] and [[Clinical_Trials|clinical trials]].


* Median survival: Only '''2.0 months''' in population-based data
=== Cytoreductive Surgery and HIPEC ===
* Hazard ratio of 2.85 relative to epithelioid histology
* Generally considered poor candidates for aggressive surgical intervention
* May benefit from palliative PIPAC or chemotherapy
* Even with CRS/HIPEC, outcomes are significantly worse than epithelioid


=== Biphasic/Mixed Peritoneal Mesothelioma ===
CRS/HIPEC is the established standard of care for selected patients with peritoneal mesothelioma and represents the most significant advance in treatment of this disease.<ref name="dandell2" /><ref name="pmc5674249" />


Biphasic contains both epithelioid and sarcomatoid components:
The procedure involves two phases. First, cytoreductive surgery removes all visible tumor through peritonectomies (excision of affected peritoneal surfaces) and visceral resections as needed. A complete parietal peritonectomy is often performed because up to 54% of normal-appearing peritoneum may harbor microscopic disease.<ref name="pmc5674249" /> Second, immediately following surgery, heated chemotherapy (cisplatin, at 41–42°C) is circulated directly within the abdominal cavity for 60–90 minutes to address microscopic residual disease.<ref name="mlc1" /><ref name="pmc5674249" />


* Represents 8–13% of surgical cases
Completeness of cytoreduction (CC score) is the strongest independent predictor of survival. CC-0 (no residual disease) and CC-1 (residual tumor less than 2.5 mm) are achieved in approximately 67% of patients and are associated with the best outcomes. CC-2 and CC-3 scores are associated with significantly worse survival, and HIPEC provides no benefit in patients with suboptimal cytoreduction.<ref name="pmc4754312" />
* Intermediate prognosis (HR 1.49 relative to epithelioid)
* Treatment decisions depend on proportion of sarcomatoid component
* Patients with predominantly epithelioid features may be candidates for CRS/HIPEC


=== Well-Differentiated Papillary Mesothelioma (WDPM) ===
Key outcomes data from major studies:


WDPM is a rare subtype comprising 0.3–5% of all mesothelioma:
* '''Yan et al. multi-institutional study''' (401 patients, 29 centers): Median overall survival 53 months; 5-year survival 47%<ref name="yan2009" />
* '''Helm et al. meta-analysis''' (1,047 patients, 20 publications): 5-year survival 42%<ref name="pmc4754312" />
* '''Feldman et al. (NCI)''' (49 patients): Median survival 92 months; 5-year survival 59%<ref name="pmc5674249" />
* '''Sugarbaker multimodality (CRS+HIPEC+NIPEC)''': Approximately 80% 5-year survival in selected patients<ref name="sugarbaker2022" />


* Most common in young women
=== Systemic Chemotherapy ===
* Generally considered of '''low malignant potential'''—most cases are benign
* Excellent prognosis with 5+ year and sometimes decades-long survival
* Conservative surgical resection typically adequate; aggressive CRS/HIPEC not routinely recommended
* 2024 Memorial Sloan Kettering series: No WDPM-related mortality
* Premenopausal presentation associated with best outcomes


== What Emerging Therapies Show Promise? ==
Pemetrexed plus cisplatin is the standard first-line systemic regimen for patients with surgically unresectable peritoneal mesothelioma.<ref name="dandell3" /><ref name="pmc4754312" /> Response rates are 25–36%, with median survival of approximately 12.1–13.1 months and disease control rates of approximately 71%.<ref name="pmc4754312" /> Systemic chemotherapy is primarily used as palliative therapy or as a strategy to assess tumor biology before considering surgical referral — though evidence suggests better outcomes when chemotherapy is given after rather than before CRS/HIPEC.<ref name="pmc5674249" />


=== Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) ===
=== Immunotherapy ===


PIPAC is an '''emerging minimally invasive treatment''' delivering chemotherapy as a pressurized aerosol directly into the abdominal cavity during laparoscopy. Key applications in peritoneal mesothelioma:<ref name="ncimeso" /><ref name="mesonethipec">[https://mesothelioma.net/heated-intraperitoneal-chemotherapy/ Heated Intraperitoneal Chemotherapy (HIPEC) | Mesothelioma.net]</ref>
The CheckMate 743 trial, which established nivolumab plus ipilimumab as a first-line standard for pleural mesothelioma, enrolled very few peritoneal patients (18 of 571 total), preventing meaningful subgroup analysis.<ref name="pmc6436227" /> However, accumulating real-world evidence supports immunotherapy activity in peritoneal mesothelioma:


* '''Palliative Treatment:''' For patients with unresectable disease not eligible for CRS/HIPEC
* A 2025 French real-world cohort of 22 unresectable peritoneal mesothelioma patients treated with immune checkpoint inhibitors demonstrated median progression-free survival of 10 months and median overall survival of 16.8 months, with an objective response rate of 30%.<ref name="ejc2025" />
* '''Downstaging/Conversion Therapy:''' Can convert initially unresectable disease (PCI >30) to resectable disease enabling subsequent CRS/HIPEC. A 2025 case series reported two patients with PCI >30 successfully downstaged by PIPAC to achieve complete cytoreduction.
* A 2024 case report documented a major sustained response to first-line nivolumab plus ipilimumab in a patient with BAP1 loss.<ref name="pmc11291227" />
* '''Long-Term Survival:''' One remarkable case achieved '''7-year survival''' with 24 consecutive PIPAC procedures using cisplatin and doxorubicin
* The NCI Phase II trial (NCT05041062) is actively investigating perioperative nivolumab plus ipilimumab combined with CRS/HIPEC for resectable disease.<ref name="nci2022" />
* '''Safety Profile:''' ISSPP PIPAC database (2020–2024) reported 3,224 PIPAC treatments in 1,126 patients with only 0.7% major complication rate and 57–75% complete or major response rates
* '''Combined Approach:''' Patients receiving PIPAC combined with CRS/HIPEC survived '''33.5 months''' on average


=== Immunotherapy and Checkpoint Inhibitors ===
BAP1 loss is associated with a more inflamed tumor microenvironment, potentially predicting immunotherapy responsiveness.<ref name="pmc6436227" />


Checkpoint inhibitors are showing emerging activity in peritoneal mesothelioma, though the disease was largely excluded from the landmark CheckMate 743 trial (only 18 of 571 patients):<ref name="ncimeso" /><ref name="mesonetimmuno">[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma | Mesothelioma.net]</ref>
=== PIPAC (Emerging Minimally Invasive Approach) ===


* '''2024 Real-World Analysis:''' 221 peritoneal mesothelioma patients sequenced; 20% received immunotherapy
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) delivers chemotherapy as a pressurized aerosol into the abdominal cavity during minimally invasive laparoscopy.<ref name="mlc2" /> PIPAC serves two roles: palliative treatment for patients ineligible for CRS/HIPEC, and downstaging therapy to convert initially unresectable disease (PCI >30) to resectable disease. A 2025 case series reported two patients with PCI >30 successfully downstaged by PIPAC to achieve complete cytoreduction at subsequent surgery.<ref name="amjcaserep2025" /> The ISSPP PIPAC database (2020–2024) encompassed 3,224 treatments in 1,126 patients with a major complication rate of only 0.7%.<ref name="degruyter2025" />
* '''Case Reports:''' Major and sustained responses to first-line nivolumab + ipilimumab documented in BAP1-negative tumors
* '''2025 French Cohort:''' 22 unresectable peritoneal mesothelioma patients with ICI-based therapy showed median OS of 16.8 months and 30% objective response rate
* '''NCI Phase II Trial (NCT05041062):''' Currently investigating perioperative nivolumab + ipilimumab combined with CRS/HIPEC
* '''MIST5 Trial (2024):''' Niraparib (PARP inhibitor) + dostarlimab (anti-PD-1) showed clinical activity in platinum-sensitive relapsed mesothelioma


BAP1 loss in peritoneal mesothelioma is associated with a more inflamed tumor microenvironment, potentially making these tumors more responsive to immune checkpoint inhibitors.<ref name="pmcbap1" />
== Prognosis and Survival ==


=== Other Emerging Approaches ===
Peritoneal mesothelioma treated with CRS/HIPEC has a substantially better prognosis than pleural mesothelioma. Population-based overall median survival is approximately 11.6 months, but this reflects many patients who do not undergo surgical treatment.<ref name="pmc9818958" /> With optimal CRS/HIPEC, peritoneal mesothelioma 5-year survival (47%) far exceeds the approximately 5% 5-year survival typically reported for pleural mesothelioma.<ref name="mesnet1" />


* '''Targeted BAP1 Therapies:''' While no BAP1-specific therapy is approved, EZH2 inhibitors are under investigation as BAP1 loss leads to EZH2 dependence<ref name="pmcbap1" />
For [[Survival_Statistics|survival statistics]] across mesothelioma types, see the linked reference page.
* '''Anti-VEGF Therapy:''' Bevacizumab + chemotherapy showed promise in pleural mesothelioma and is being tested in peritoneal disease
* '''Bispecific Antibodies:''' Volrustomig (anti-PD-1/CTLA-4 bispecific) under investigation in phase 3 trials
* '''Telomerase-Targeting:''' TERT promoter mutations occur in ~12% of mesothelioma; therapeutic approaches in preclinical development


== Why Are Women's Outcomes Significantly Better? ==
=== Survival by Histologic Subtype ===


One of the most striking features of peritoneal mesothelioma is the '''superior survival in women compared to men'''—a pattern not observed in pleural mesothelioma:
Histologic subtype is a critical prognostic determinant:


{| class="wikitable" style="width:100%; margin:1em 0;"
* '''Epithelioid''' (79–91% of surgical cases): Best prognosis; independently associated with improved survival on multivariate analysis<ref name="pmc9818958" /><ref name="pmc5674249" />
|-
* '''Sarcomatoid''' (~3% of cases): Most aggressive; median survival 2.0 months in population-based data<ref name="pmc9818958" />
! style="background:#1a5276; color:white; padding:10px;" | Survival Metric
* '''Biphasic''' (~4% of cases): Intermediate prognosis; hazard ratio 1.49 relative to epithelioid<ref name="pmc9818958" />
! style="background:#1a5276; color:white; padding:10px;" | Women
* '''Well-differentiated papillary mesothelioma''' (WDPM): Low malignant potential; most patients survive for years to decades without aggressive treatment<ref name="pmc11466981" />
! style="background:#1a5276; color:white; padding:10px;" | Men
|-
| 1-Year Survival || 89% || 77%
|-
| 3-Year Survival || 76% || 50%
|-
| 5-Year Survival || '''68%''' || '''39%'''
|}


Female sex is an '''independent predictor of improved survival''' (HR 0.66; 95% CI: 0.58–0.76) on multivariate analysis. Contributing factors include:
=== Key Prognostic Factors ===


* '''Younger age at diagnosis:''' Women typically present 5–10 years younger than men
Factors independently associated with improved survival include: epithelioid histology, complete cytoreduction (CC-0 or CC-1), female sex, younger age, PCI below 15–17, absence of lymph node metastasis, and use of cisplatin-based HIPEC (versus mitomycin C).<ref name="pmc5674249" /><ref name="pmc4754312" /><ref name="dandell4" /> A normal preoperative CA-125 level (35 U/mL or below) is associated with 5-year survival of 82% versus 42% with elevated CA-125.<ref name="pmc5674249" />
* '''Better performance status:''' Women often have fewer comorbidities and better baseline health
* '''Epithelioid predominance:''' Women are more likely to have epithelioid histology
* '''Potential hormonal protection:''' Premenopausal women have significantly better outcomes than postmenopausal women
* '''Selection bias in surgical population:''' Women selected for CRS/HIPEC may represent a more favorable risk group


The superior outcomes in women underscore the importance of '''age and performance status''' as prognostic factors, independent of disease biology. <ref name="ncimeso" /><ref name="mesonetsurgery">[https://mesothelioma.net/mesothelioma-surgery/ Mesothelioma Surgery | Mesothelioma.net]</ref>
Long-term survival is well-documented. Repeat CRS/HIPEC for recurrence yields approximately 46% 5-year survival.<ref name="pmc6204413" />


== What Legal Options Exist for Peritoneal Mesothelioma Patients? ==
== Asbestos Exposure and Causes ==


=== Unique Causation Challenges ===
=== How Asbestos Reaches the Peritoneum ===


The lower asbestos attribution rate for peritoneal mesothelioma (60–80% vs. ~96% for pleural) creates distinct legal challenges. Defense attorneys may argue weaker causal linkage, particularly when:
The mechanism by which asbestos fibers reach the peritoneum is not fully established. Three pathways are proposed:<ref name="pmc5674249" /><ref name="atsdr" />


* The claimant is female with no direct occupational exposure
# '''Ingestion via mucociliary clearance''': Inhaled fibers trapped in the airways are cleared upward, swallowed, and enter the gastrointestinal tract, where they may penetrate through the gut wall into the peritoneum
* No documented occupational asbestos contact history exists
# '''Diaphragmatic translocation''': Fibers in the pleural space migrate through diaphragmatic lymphatics or stomata into the peritoneal cavity
* Latency period is shorter than expected (20 years vs. 30–40 years for pleural)
# '''Hematogenous/lymphatic spread''': Fibers may reach abdominal sites via the bloodstream or lymphatic system
* The claimant carries a BAP1 mutation


Establishing causation requires:
Asbestos fibers have been found in the omentum and mesentery of patients with peritoneal mesothelioma, supporting the GI ingestion pathway.<ref name="pmc5674249" /> Once lodged in the peritoneum, fibers cause chronic inflammation, chromosomal instability, and ultimately malignant transformation of mesothelial cells.<ref name="pmc5674249" />


* '''Expert medical testimony''' linking asbestos to peritoneal mesothelioma
=== Latency Period ===
* '''Occupational and residential exposure history''', including secondary/paraoccupational exposure documentation
* '''Fiber pathway evidence''' (ingestion, lymphatic translocation, peritoneal seeding)
* '''Lung fiber burden analysis''' from tissue samples
* '''Epidemiological evidence''' showing dose-response relationships and risk elevation even at low-dose exposures
* '''Genetic testing''' for BAP1 mutations—carriers with minimal asbestos exposure can develop mesothelioma


=== Compensation Mechanisms ===
The latency period from initial asbestos exposure to peritoneal mesothelioma diagnosis is typically 20–50 years, though some cases — particularly those associated with BAP1 germline mutations — may present after only 8–10 years.<ref name="dandell5" /> The average age at diagnosis is 62–65 years, reflecting decades of latent disease development.<ref name="pmc4754312" /><ref name="pmc9818958" />


Peritoneal mesothelioma patients have access to multiple compensation sources:<ref name="mlcasbestosis">[https://www.mesotheliomalawyercenter.org/asbestos/asbestosis/ Asbestosis Information | Mesothelioma Lawyer Center]</ref>
=== Non-Asbestos Risk Factors ===


* '''Asbestos Bankruptcy Trust Funds:''' Approximately $25–30 billion remains available across 60+ active trusts. Average combined payouts are '''$300,000 to $400,000''' across multiple funds, with individual trust payments ranging from '''$7,000 to $1.2 million'''. Trust fund claims require only documented exposure to manufacturers' products—no need to prove negligence.
A meaningful minority of peritoneal mesothelioma cases occur without asbestos exposure. Known or proposed non-asbestos risk factors include:<ref name="pmc5674249" />


* '''Lawsuit Settlements:''' Average settlement amounts fall between '''$1 million and $1.4 million''', with trial verdicts averaging approximately '''$2.4 million'''. Notable verdicts include a 2022 California award of $53.3 million and a 2025 Boston jury verdict of $8 million to an 84-year-old woman with mesothelioma linked to talcum powder exposure.
* '''BAP1 germline mutations''': Present in approximately 12% of mesothelioma patients; significantly increases susceptibility and can dramatically shorten latency
* '''Prior abdominal radiation therapy'''
* '''Chronic peritoneal inflammation''' (e.g., Mediterranean familial fever)
* '''Secondary/paraoccupational exposure''' in women: Laundering contaminated work clothing, physical contact with exposed family members, and household dust are primary exposure routes for many female patients


* '''Simultaneous Claims:''' Patients can pursue both trust fund claims and lawsuits simultaneously to maximize total recovery, and trust fund payments do not reduce other compensation sources including settlement proceeds or VA benefits.
=== Occupational Exposure Groups ===


{| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
Workers at historically elevated peritoneal mesothelioma risk include asbestos miners and millers, insulation workers, shipyard workers, pipe fitters, boilermakers, and construction tradespeople exposed to asbestos-containing products. Asbestos fibers have also been found in the omentum of patients whose only documented exposure was secondary or environmental.<ref name="mesnet2" /> See the [[Corporate_Asbestos_Coverup|corporate concealment]] page for historical context on industry knowledge of asbestos risks.
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "Women with peritoneal mesothelioma often dismiss their exposure as 'just laundry' when in reality, secondary exposure through contaminated work clothing can deliver significant fiber doses. These cases deserve full investigation and aggressive prosecution—we have recovered substantial compensation for women whose exposure came entirely through paraoccupational means."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
|}


== Get Help Today ==
== Legal Rights and Compensation ==


{| style="width:100%; background:linear-gradient(135deg, #1a5276 0%, #2980b9 100%); border-radius:8px; margin:1em 0;"
Patients diagnosed with peritoneal mesothelioma have the same legal rights to compensation as those with pleural mesothelioma, though the legal pathway may present additional complexities due to the lower asbestos attribution rate.
|-
| style="padding:25px; text-align:center; color:white;" |
<span style="font-size:1.4em; font-weight:bold;">Free Case Evaluation for Peritoneal Mesothelioma</span>
 
Peritoneal mesothelioma patients and families face unique diagnostic, treatment, and legal challenges. Our experienced legal team specializes in complex mesothelioma cases, including those involving secondary/paraoccupational exposure, genetic predisposition, and the challenging causation issues specific to peritoneal disease.
 
'''What We Offer:'''
✓ Free, confidential case evaluation by experienced mesothelioma attorneys
✓ No upfront costs—we only recover fees if you receive compensation
✓ Nationwide representation for peritoneal mesothelioma cases
✓ Help identifying all responsible manufacturers and trust funds
✓ Coordination with specialized treatment centers for CRS/HIPEC and emerging therapies
 
<span data-nosnippet class="noai-content">[https://www.mesotheliomalawyercenter.org/asbestos/ '''Request Your Free Case Review Today →''']</span>
|}
 
{{CTA Box}}


{{Statute Warning}}
{{Statute Warning}}


== References ==
=== Asbestos Trust Funds ===


<ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Malignant Mesothelioma Treatment (PDQ) – Patient Version, National Cancer Institute]</ref>
More than 60 asbestos bankruptcy trusts hold an estimated $25–30 billion available for qualified claimants.<ref name="dandell6" /> Individual trust payments range from $7,000 to $1.2 million per trust, with patients typically filing claims against multiple trusts.<ref name="mlc3" /> The average total recovery across all trust funds is approximately $300,000–$400,000.<ref name="mesatty1" /> Peritoneal mesothelioma patients are eligible for trust fund claims on the same basis as pleural mesothelioma patients. For more information on filing, see [[Asbestos_Trust_Funds|asbestos trust funds]] and [[Trust_Fund_Filing_Guidance|trust fund claims]].


<ref name="pmcyan">[https://pubmed.ncbi.nlm.nih.gov/19917862/ Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. ''J Clin Oncol.'' 2009;27(36):6237-6242.]</ref>
=== Lawsuits and Verdicts ===


<ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref>
Average mesothelioma lawsuit settlements fall between $1 million and $1.4 million.<ref name="dandell6" /> Trial verdicts average approximately $2.4 million, with notable cases far exceeding these averages — a 2022 California jury awarded $53.3 million to a mesothelioma patient, and a 2025 Boston jury awarded $8 million to a woman whose disease was linked to talcum powder use.<ref name="mlc4" /> Patients may pursue both trust fund claims and personal injury lawsuits simultaneously to maximize total compensation. See the [[Mesothelioma_Claim_Process|claims process]] and [[Statute_of_Limitations_by_State|statute of limitations]] pages for state-specific filing deadlines.


<ref name="pmchelm">[https://pubmed.ncbi.nlm.nih.gov/25124472/ Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. ''Ann Surg Oncol.'' 2015;22(5):1686-1693.]</ref>
=== Unique Legal Challenges ===


<ref name="pmcbap1">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436227/ Ladanyi M. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. ''Genome Med.'' 2019;11(1):18.]</ref>
Peritoneal mesothelioma cases present distinctive legal challenges. Defense attorneys may argue that the lower asbestos attribution rate (60–80% versus 96% for pleural) weakens the causal link. Female plaintiffs with secondary exposure claims, patients with BAP1 mutations, and patients with shorter latency periods all face potential challenges to causation arguments. Experienced mesothelioma attorneys address these challenges through expert medical testimony, occupational and residential exposure history, epidemiological studies of dose-response relationships, and — where relevant — fiber burden analysis and genetic testing evidence.<ref name="dandell6" /><ref name="mesatty2" />


<ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases | Mesothelioma Lawyer Center]</ref>
=== Get Help ===


<ref name="dandellperitoneal">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs. Peritoneal Mesothelioma: Key Differences | Danziger & De Llano]</ref>
* [https://dandell.com/mesothelioma/peritoneal-mesothelioma/ Free consultation for peritoneal mesothelioma — Danziger &amp; De Llano] — Call (866) 222-9990
* [https://mesotheliomalawyersnearme.com/quiz/ Find a mesothelioma attorney near you] — Free case evaluation
* [https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal mesothelioma patient resources] — Mesothelioma.net


<ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma | Mesothelioma.net]</ref>
<span data-nosnippet class="noai-content">
{{CTA Box|}}
</span>


<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide | Danziger & De Llano]</ref>
== Frequently Asked Questions ==


<ref name="mlccancer">[https://www.mesotheliomalawyercenter.org/asbestos/cancer/ Asbestos Cancer | Mesothelioma Lawyer Center]</ref>
=== What is peritoneal mesothelioma? ===


<ref name="mlcasbestos">[https://www.mesotheliomalawyercenter.org/asbestos/ Asbestos Exposure Information | Mesothelioma Lawyer Center]</ref>
Peritoneal mesothelioma is a cancer of the peritoneum — the thin membrane lining the abdominal cavity and covering the abdominal organs. It is caused primarily by asbestos fiber ingestion or fiber translocation from the pleural space and accounts for approximately 7–30% of all mesothelioma diagnoses. Approximately 800 new cases are diagnosed in the United States each year.<ref name="pmc4754312" /><ref name="pmc9818958" />


<ref name="dandellcauses">[https://dandell.com/asbestos-exposure/mesothelioma-symptoms-causes-legal-options/ Mesothelioma: Symptoms, Causes & Legal Options | Danziger & De Llano]</ref>
=== How is peritoneal mesothelioma different from pleural mesothelioma? ===


<ref name="mlcexposure">[https://www.mesotheliomalawyercenter.org/asbestos/exposure/ Asbestos Exposure Risks | Mesothelioma Lawyer Center]</ref>
Peritoneal mesothelioma develops in the abdominal lining rather than the lung lining, presents with abdominal symptoms (ascites, bloating, pain) rather than chest symptoms, has a near-equal male-to-female ratio (versus 4:1 male predominance in pleural disease), and is more amenable to surgical treatment via CRS/HIPEC. When optimally treated, peritoneal mesothelioma has a substantially better prognosis — 47% 5-year survival with CRS/HIPEC versus approximately 5% for pleural mesothelioma.<ref name="pmc5674249" /><ref name="dandell3" />


<ref name="dandellrisks">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cancer-risks/ Mesothelioma Cancer Risks | Danziger & De Llano]</ref>
=== What is HIPEC and who is eligible? ===


<ref name="mesonetchemo">[https://mesothelioma.net/mesothelioma-chemotherapy/ Mesothelioma Chemotherapy | Mesothelioma.net]</ref>
HIPEC (hyperthermic intraperitoneal chemotherapy) is a treatment in which heated chemotherapy is circulated directly inside the abdominal cavity immediately after cytoreductive surgery removes all visible tumor. The heat enhances chemotherapy penetration and helps kill microscopic residual cancer cells.<ref name="mlc2" /> Candidates generally have a PCI score below 20, epithelioid or biphasic histology, adequate performance status, and preserved small bowel anatomy. All potentially eligible patients should be evaluated by a peritoneal surface oncology specialist at a high-volume center.<ref name="dandell2" />


<ref name="mesonethipec">[https://mesothelioma.net/heated-intraperitoneal-chemotherapy/ Heated Intraperitoneal Chemotherapy (HIPEC) | Mesothelioma.net]</ref>
=== What is the survival rate for peritoneal mesothelioma? ===


<ref name="mesonetimmuno">[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma | Mesothelioma.net]</ref>
Survival varies significantly by treatment. Without treatment, median survival is approximately 6 months. With systemic chemotherapy alone, median survival is approximately 12 months. With CRS/HIPEC, median survival is 34–92 months (averaging around 53 months in the largest multi-institutional study), and 5-year survival rates of 41–59% have been reported at major centers.<ref name="yan2009" /><ref name="sugarbaker2022" /> Patients with epithelioid histology, low PCI scores, and female sex have the best outcomes.<ref name="pmc4754312" />


<ref name="mesonetsurgery">[https://mesothelioma.net/mesothelioma-surgery/ Mesothelioma Surgery | Mesothelioma.net]</ref>
=== Can you get compensation for peritoneal mesothelioma without a documented asbestos exposure? ===


<ref name="mesonetprognosis">[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis | Mesothelioma.net]</ref>
Yes. Even when a patient cannot identify a specific occupational exposure, compensation may still be recoverable. Secondary (paraoccupational) exposure — such as from laundering contaminated clothing or household asbestos dust — is a recognized legal basis for claims. BAP1 germline mutations combined with any level of asbestos exposure can establish causation. Approximately 20–40% of peritoneal mesothelioma cases lack documented occupational exposure, and experienced mesothelioma attorneys are accustomed to building these cases.<ref name="dandell6" /><ref name="mesatty1" /> Contact a qualified mesothelioma attorney to evaluate your specific circumstances.


<ref name="dandellcomp">[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation | Danziger & De Llano]</ref>


<ref name="dandelllatency">[https://dandell.com/asbestos-exposure/how-long-does-it-take-from-exposure-to-mesothelioma-diagnosis/ Asbestos Exposure to Mesothelioma Timeline | Danziger & De Llano]</ref>
== See Also ==
 
* [[Heated Chemotherapy (HITHOC and HIPEC)|Heated Chemotherapy (HITHOC and HIPEC)]]
<ref name="mlclung">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/lung-cancer/ Lung Cancer from Asbestos | Mesothelioma Lawyer Center]</ref>
* [[Palliative Care|Palliative Care for Mesothelioma]]
 
* [[Mesothelioma Nutrition and Supportive Care|Mesothelioma Nutrition and Supportive Care]]
<ref name="mlcasbestosis">[https://www.mesotheliomalawyercenter.org/asbestos/asbestosis/ Asbestosis Information | Mesothelioma Lawyer Center]</ref>
* [[Gene Therapy|Gene Therapy]]
 
<ref name="mesoattperitoneal">[https://mesotheliomaattorney.com/mesothelioma/types/peritoneal/ Peritoneal Mesothelioma | Mesothelioma Attorney]</ref>
 
<ref name="mesoatttreatment">[https://mesotheliomaattorney.com/mesothelioma/treatment/ Mesothelioma Treatment | Mesothelioma Attorney]</ref>
 
<ref name="mesoattcomp">[https://mesotheliomaattorney.com/mesothelioma/compensation/ Mesothelioma Compensation | Mesothelioma Attorney]</ref>
 
<ref name="mesoatttrusts">[https://mesotheliomaattorney.com/mesothelioma/trust-funds/ Asbestos Trust Funds | Mesothelioma Attorney]</ref>
 
<ref name="dandellguide">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cancer-guide/ Mesothelioma Cancer Guide | Danziger & De Llano]</ref>
 
<ref name="dandellcure">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cure-support/ Mesothelioma Cure & Support | Danziger & De Llano]</ref>


== References ==
<references>
<ref name="pmc4754312">[https://pmc.ncbi.nlm.nih.gov/articles/PMC4754312/ Diagnosis and management of patients with malignant peritoneal mesothelioma], PMC4754312, Journal of Gastrointestinal Oncology</ref>
<ref name="pmc5674249">[https://pmc.ncbi.nlm.nih.gov/articles/PMC5674249/ Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma], PMC5674249, Translational Lung Cancer Research</ref>
<ref name="pmc9818958">[https://pmc.ncbi.nlm.nih.gov/articles/PMC9818958/ Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States], PMC9818958, Cancers (SEER 2000–2018 analysis)</ref>
<ref name="yan2009">[https://ascopubs.org/doi/10.1200/JCO.2009.23.9640 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-institutional Experience], Journal of Clinical Oncology, Yan et al. 2009 (401 patients, 29 centers)</ref>
<ref name="dandell1">[https://dandell.com/mesothelioma/ Mesothelioma Overview and Asbestos Causation], Danziger &amp; De Llano, Mesothelioma Attorneys</ref>
<ref name="dandell2">[https://dandell.com/mesothelioma/peritoneal-mesothelioma/ Peritoneal Mesothelioma Treatment and HIPEC], Danziger &amp; De Llano, Mesothelioma Attorneys</ref>
<ref name="dandell3">[https://dandell.com/mesothelioma/treatment/ Mesothelioma Treatment Options], Danziger &amp; De Llano, Mesothelioma Attorneys</ref>
<ref name="dandell4">[https://dandell.com/mesothelioma/prognosis/ Mesothelioma Prognosis and Survival Factors], Danziger &amp; De Llano, Mesothelioma Attorneys</ref>
<ref name="dandell5">[https://dandell.com/mesothelioma/asbestos-exposure/ Asbestos Exposure and Latency Period], Danziger &amp; De Llano, Mesothelioma Attorneys</ref>
<ref name="dandell6">[https://dandell.com/mesothelioma/compensation/ Mesothelioma Compensation and Legal Rights], Danziger &amp; De Llano, Mesothelioma Attorneys</ref>
<ref name="mlc1">[https://www.mesotheliomalawyercenter.org/mesothelioma/peritoneal/ Peritoneal Mesothelioma Overview], Mesothelioma Lawyer Center</ref>
<ref name="mlc2">[https://www.mesotheliomalawyercenter.org/mesothelioma/treatment/hipec/ HIPEC Treatment for Peritoneal Mesothelioma], Mesothelioma Lawyer Center</ref>
<ref name="mlc3">[https://www.mesotheliomalawyercenter.org/mesothelioma/asbestos-trust-funds/ Asbestos Trust Fund Claims for Mesothelioma], Mesothelioma Lawyer Center</ref>
<ref name="mlc4">[https://www.mesotheliomalawyercenter.org/mesothelioma/lawsuit/ Mesothelioma Lawsuit Settlements and Verdicts], Mesothelioma Lawyer Center</ref>
<ref name="mesnet1">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma: Survival and Prognosis], Mesothelioma.net</ref>
<ref name="mesnet2">[https://mesothelioma.net/asbestos-ingestion/ Asbestos Ingestion and Peritoneal Mesothelioma], Mesothelioma.net</ref>
<ref name="mesatty1">[https://www.mesotheliomaattorney.com/compensation/trust-funds/ Asbestos Trust Fund Compensation Guide], MesotheliomaAttorney.com</ref>
<ref name="mesatty2">[https://www.mesotheliomaattorney.com/peritoneal-mesothelioma/ Peritoneal Mesothelioma Legal Rights], MesotheliomaAttorney.com</ref>
<ref name="nature2020">[https://www.nature.com/articles/s41598-020-70044-8 Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma], Scientific Reports, 2020</ref>
<ref name="pmc6436227">[https://pmc.ncbi.nlm.nih.gov/articles/PMC6436227/ Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma], PMC6436227, Annals of Oncology</ref>
<ref name="pmc11291227">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11291227/ Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature], PMC11291227, Frontiers in Oncology, 2024</ref>
<ref name="ejc2025">[https://www.sciencedirect.com/science/article/abs/pii/S0959804925009529 Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma], European Journal of Cancer, 2025</ref>
<ref name="nci2022">[https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-00616 NCT05041062 — Perioperative Nivolumab and Ipilimumab for Peritoneal Mesothelioma], National Cancer Institute Clinical Trials</ref>
<ref name="sugarbaker2022">[https://www.scientificarchives.com/public/assets/articles/article-pdf-1664443764-722.pdf Long-term Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma], Sugarbaker PH, Scientific Archives, 2022</ref>
<ref name="pmc6204413">[https://pmc.ncbi.nlm.nih.gov/articles/PMC6204413/ Update on the management of malignant peritoneal mesothelioma], PMC6204413, Annals of Surgical Oncology</ref>
<ref name="pmc11466981">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11466981/ Clinical Characteristics and Outcomes of Patients with Well-Differentiated Papillary Mesothelioma], PMC11466981, Annals of Surgical Oncology, 2024</ref>
<ref name="amjcaserep2025">[https://amjcaserep.com/abstract/full/idArt/950407 Neoadjuvant PIPAC for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma], American Journal of Case Reports, 2025</ref>
<ref name="degruyter2025">[https://pmc.ncbi.nlm.nih.gov/articles/PMC8100694/ The emergence of pressurized intraperitoneal aerosol chemotherapy as a palliative treatment option for patients with diffuse peritoneal metastases], PMC8100694, Journal of Peritoneal and Retroperitoneal Diseases</ref>
<ref name="atsdr">[https://www.atsdr.cdc.gov/hac/asbestospanel/AsbestosExpertPanel.pdf Report on the Expert Panel on Health Effects of Asbestos and Synthetic Vitreous Fibers], ATSDR / CDC</ref>
<ref name="pmc11652017">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11652017/ Imaging, pathological and molecular detection of malignant peritoneal mesothelioma: a case description], PMC11652017, Frontiers in Oncology</ref>
</references>
</references>


[[Category:Peritoneal Mesothelioma]]
[[Category:Mesothelioma Types]]
[[Category:Mesothelioma Types]]
[[Category:Mesothelioma Treatment]]
[[Category:Medical Information]]
[[Category:Cancer Treatment]]
[[Category:Treatment]]
[[Category:Asbestos-Related Disease]]
[[Category:Legal Rights]]
[[Category:CRS/HIPEC]]
[[Category:Asbestos Diseases]]
[[Category:Abdominal Cancer]]
[[Category:Peritoneal Cancer]]
[[Category:Mesothelioma Survival]]
[[Category:Patient Resources]]
[[Category:PIPAC Treatment]]
[[Category:Diagnosis]]
[[Category:Immunotherapy]]

Latest revision as of 01:11, 6 April 2026


Peritoneal Mesothelioma
Also Known As Malignant Peritoneal Mesothelioma (MPM)
Location Peritoneum (abdominal lining)
Annual US Cases ~800 new cases per year
Percentage of Meso 7–30% of all mesothelioma
Median Survival (HIPEC) ~53 months
5-Year Survival 30–50% with optimal treatment
Peak Latency 20–50 years

Peritoneal Mesothelioma

Malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer arising from the mesothelial cells lining the peritoneum — the membrane surrounding the abdominal cavity and organs.[1] It is the second most common form of mesothelioma after pleural mesothelioma, accounting for approximately 7–30% of all diagnoses.[2] Approximately 800 new cases are diagnosed in the United States each year.[1]

Unlike pleural mesothelioma, peritoneal mesothelioma has a near-equal male-to-female ratio and a meaningful proportion of cases (20–40%) occur in patients without documented asbestos exposure.[2] The disease has been transformed by the development of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), which has extended median survival from approximately 12 months to 53 months or more in selected patients.[3]

Overview

Definition and Incidence

Peritoneal mesothelioma develops in the peritoneum, the serosal membrane lining the abdominal cavity and covering the abdominal organs.[1] The disease remains rare, with an age-adjusted incidence rate of approximately 1.02 cases per 1,000,000 person-years in the United States based on SEER data from 2000–2018.[4] US incidence has remained broadly stable over that period, though unadjusted case counts increased by 64.9% driven primarily by new diagnoses in women.[4]

Demographics

Peritoneal mesothelioma differs meaningfully from pleural mesothelioma in patient demographics:

  • Male-to-female ratio: Approximately 1.2:1 — dramatically more balanced than pleural mesothelioma's 4:1 male predominance[4]
  • Median age at diagnosis: 50–65 years[1][4]
  • Race/ethnicity: White patients account for approximately 75% of cases in SEER data[4]
  • Female representation in surgical series: Some CRS/HIPEC centers report that women comprise 59% of operated patients[1]

Women with peritoneal mesothelioma consistently demonstrate superior outcomes after treatment, with 5-year survival rates of 68% in women versus 39% in men.[2]

Asbestos Attribution

Asbestos is the primary known cause of peritoneal mesothelioma, but the attribution rate is lower than for pleural disease. Approximately 60–80% of peritoneal mesothelioma cases have documented asbestos exposure, meaning 20–40% of patients have no identifiable occupational or environmental asbestos contact.[2] By contrast, approximately 96% of pleural mesothelioma cases are attributable to asbestos.[5] The weaker attribution in peritoneal cases reflects a higher proportion of female patients with secondary (paraoccupational) exposure, a greater role for BAP1 germline mutations, and incomplete occupational histories.

Symptoms and Diagnosis

Symptom Profile

Peritoneal mesothelioma presents with non-specific abdominal symptoms that frequently delay diagnosis by a median of 4–6 months from initial presentation.[2] The most common presenting symptoms include:

  • Abdominal distension and bloating — occurring in over 30–50% of patients[2]
  • Abdominal pain — occurring in over 30–50% of patients[2]
  • Ascites (fluid accumulation) — often the presenting clinical finding[1]
  • Weight loss and early satiety[1]
  • Nausea, fatigue, and altered bowel habits[6]
  • New-onset hernia or palpable abdominal mass (less common)[2]

Due to these non-specific symptoms, peritoneal mesothelioma is frequently misdiagnosed as ovarian cancer in women, irritable bowel syndrome, or peritoneal carcinomatosis from other primary cancers such as stomach, pancreas, or colon.[2]

Key Facts: Peritoneal Mesothelioma at a Glance

Fact Data
Annual US cases ~800 new diagnoses per year
Share of all mesothelioma 7–30% (most cited: 10–20%)
Male-to-female ratio ~1.2:1 (near-equal)
Cases with no asbestos exposure 20–40%
Median age at diagnosis 62–65 years
Latency period 20–50 years from first exposure
Median survival (untreated) ~6 months
Median survival (chemo alone) ~12 months
Median survival (CRS/HIPEC) ~53 months
5-year survival (CRS/HIPEC) 41–59%
Trust fund compensation range $7,000–$1.2 million per fund
Average lawsuit settlement $1 million–$1.4 million

Diagnostic Imaging

CT scan of the chest, abdomen, and pelvis is the initial imaging modality of choice.[1] Favorable CT findings include ascites with minimal soft-tissue masses and preserved bowel architecture. Unfavorable CT findings include large nodular thickening with marked bowel distortion, which predicts incomplete cytoreduction.[1]

MRI with diffusion-weighted imaging can predict the peritoneal cancer index (PCI) preoperatively with good accuracy.[1] FDG-PET/CT demonstrates uptake along the peritoneum but has unclear utility for initial staging.[7]

Tissue Biopsy and Immunohistochemistry

Diagnostic laparoscopy with biopsy is the preferred approach to obtain tissue, as it allows simultaneous visualization of tumor burden and PCI assessment.[2][1] Paracentesis and cytology of ascitic fluid has limited diagnostic yield and is not recommended as a sole approach.[2]

A panel of immunohistochemical markers is required to confirm diagnosis. Positive mesothelial markers include calretinin, cytokeratin 5/6, WT-1, and D2-40. Negative markers used to exclude adenocarcinoma include BerEP4, CEA, and TTF-1.[2] Loss of BAP1 nuclear expression is highly specific for distinguishing malignant from benign mesothelial proliferation.[2]

Peritoneal Cancer Index (PCI) Scoring

The Peritoneal Cancer Index (PCI) is the standard tool for quantifying disease burden, dividing the abdomen into 13 regions and assigning each a lesion-size score of 0–3. The maximum PCI score is 39.[1] PCI correlates directly with prognosis and surgical eligibility:

  • PCI 1–10 (Stage I): 5-year overall survival 87%[1]
  • PCI 11–20 (Stage II): 5-year overall survival 53%[1]
  • PCI ≤19: Associated with improved overall survival (p = 0.001)[8]
  • PCI ≥30: Associated with significantly worse survival (p = 0.002)[8]

Treatment Options

Peritoneal mesothelioma treatment has advanced substantially over the past two decades. The current standard of care for eligible patients combines cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). For patients who cannot undergo surgery, systemic chemotherapy and emerging immunotherapy approaches are available. For information on related options, see treatment options and clinical trials.

Cytoreductive Surgery and HIPEC

CRS/HIPEC is the established standard of care for selected patients with peritoneal mesothelioma and represents the most significant advance in treatment of this disease.[9][2]

The procedure involves two phases. First, cytoreductive surgery removes all visible tumor through peritonectomies (excision of affected peritoneal surfaces) and visceral resections as needed. A complete parietal peritonectomy is often performed because up to 54% of normal-appearing peritoneum may harbor microscopic disease.[2] Second, immediately following surgery, heated chemotherapy (cisplatin, at 41–42°C) is circulated directly within the abdominal cavity for 60–90 minutes to address microscopic residual disease.[10][2]

Completeness of cytoreduction (CC score) is the strongest independent predictor of survival. CC-0 (no residual disease) and CC-1 (residual tumor less than 2.5 mm) are achieved in approximately 67% of patients and are associated with the best outcomes. CC-2 and CC-3 scores are associated with significantly worse survival, and HIPEC provides no benefit in patients with suboptimal cytoreduction.[1]

Key outcomes data from major studies:

  • Yan et al. multi-institutional study (401 patients, 29 centers): Median overall survival 53 months; 5-year survival 47%[3]
  • Helm et al. meta-analysis (1,047 patients, 20 publications): 5-year survival 42%[1]
  • Feldman et al. (NCI) (49 patients): Median survival 92 months; 5-year survival 59%[2]
  • Sugarbaker multimodality (CRS+HIPEC+NIPEC): Approximately 80% 5-year survival in selected patients[11]

Systemic Chemotherapy

Pemetrexed plus cisplatin is the standard first-line systemic regimen for patients with surgically unresectable peritoneal mesothelioma.[12][1] Response rates are 25–36%, with median survival of approximately 12.1–13.1 months and disease control rates of approximately 71%.[1] Systemic chemotherapy is primarily used as palliative therapy or as a strategy to assess tumor biology before considering surgical referral — though evidence suggests better outcomes when chemotherapy is given after rather than before CRS/HIPEC.[2]

Immunotherapy

The CheckMate 743 trial, which established nivolumab plus ipilimumab as a first-line standard for pleural mesothelioma, enrolled very few peritoneal patients (18 of 571 total), preventing meaningful subgroup analysis.[13] However, accumulating real-world evidence supports immunotherapy activity in peritoneal mesothelioma:

  • A 2025 French real-world cohort of 22 unresectable peritoneal mesothelioma patients treated with immune checkpoint inhibitors demonstrated median progression-free survival of 10 months and median overall survival of 16.8 months, with an objective response rate of 30%.[14]
  • A 2024 case report documented a major sustained response to first-line nivolumab plus ipilimumab in a patient with BAP1 loss.[15]
  • The NCI Phase II trial (NCT05041062) is actively investigating perioperative nivolumab plus ipilimumab combined with CRS/HIPEC for resectable disease.[16]

BAP1 loss is associated with a more inflamed tumor microenvironment, potentially predicting immunotherapy responsiveness.[13]

PIPAC (Emerging Minimally Invasive Approach)

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) delivers chemotherapy as a pressurized aerosol into the abdominal cavity during minimally invasive laparoscopy.[17] PIPAC serves two roles: palliative treatment for patients ineligible for CRS/HIPEC, and downstaging therapy to convert initially unresectable disease (PCI >30) to resectable disease. A 2025 case series reported two patients with PCI >30 successfully downstaged by PIPAC to achieve complete cytoreduction at subsequent surgery.[18] The ISSPP PIPAC database (2020–2024) encompassed 3,224 treatments in 1,126 patients with a major complication rate of only 0.7%.[19]

Prognosis and Survival

Peritoneal mesothelioma treated with CRS/HIPEC has a substantially better prognosis than pleural mesothelioma. Population-based overall median survival is approximately 11.6 months, but this reflects many patients who do not undergo surgical treatment.[4] With optimal CRS/HIPEC, peritoneal mesothelioma 5-year survival (47%) far exceeds the approximately 5% 5-year survival typically reported for pleural mesothelioma.[6]

For survival statistics across mesothelioma types, see the linked reference page.

Survival by Histologic Subtype

Histologic subtype is a critical prognostic determinant:

  • Epithelioid (79–91% of surgical cases): Best prognosis; independently associated with improved survival on multivariate analysis[4][2]
  • Sarcomatoid (~3% of cases): Most aggressive; median survival 2.0 months in population-based data[4]
  • Biphasic (~4% of cases): Intermediate prognosis; hazard ratio 1.49 relative to epithelioid[4]
  • Well-differentiated papillary mesothelioma (WDPM): Low malignant potential; most patients survive for years to decades without aggressive treatment[20]

Key Prognostic Factors

Factors independently associated with improved survival include: epithelioid histology, complete cytoreduction (CC-0 or CC-1), female sex, younger age, PCI below 15–17, absence of lymph node metastasis, and use of cisplatin-based HIPEC (versus mitomycin C).[2][1][21] A normal preoperative CA-125 level (35 U/mL or below) is associated with 5-year survival of 82% versus 42% with elevated CA-125.[2]

Long-term survival is well-documented. Repeat CRS/HIPEC for recurrence yields approximately 46% 5-year survival.[22]

Asbestos Exposure and Causes

How Asbestos Reaches the Peritoneum

The mechanism by which asbestos fibers reach the peritoneum is not fully established. Three pathways are proposed:[2][23]

  1. Ingestion via mucociliary clearance: Inhaled fibers trapped in the airways are cleared upward, swallowed, and enter the gastrointestinal tract, where they may penetrate through the gut wall into the peritoneum
  2. Diaphragmatic translocation: Fibers in the pleural space migrate through diaphragmatic lymphatics or stomata into the peritoneal cavity
  3. Hematogenous/lymphatic spread: Fibers may reach abdominal sites via the bloodstream or lymphatic system

Asbestos fibers have been found in the omentum and mesentery of patients with peritoneal mesothelioma, supporting the GI ingestion pathway.[2] Once lodged in the peritoneum, fibers cause chronic inflammation, chromosomal instability, and ultimately malignant transformation of mesothelial cells.[2]

Latency Period

The latency period from initial asbestos exposure to peritoneal mesothelioma diagnosis is typically 20–50 years, though some cases — particularly those associated with BAP1 germline mutations — may present after only 8–10 years.[24] The average age at diagnosis is 62–65 years, reflecting decades of latent disease development.[1][4]

Non-Asbestos Risk Factors

A meaningful minority of peritoneal mesothelioma cases occur without asbestos exposure. Known or proposed non-asbestos risk factors include:[2]

  • BAP1 germline mutations: Present in approximately 12% of mesothelioma patients; significantly increases susceptibility and can dramatically shorten latency
  • Prior abdominal radiation therapy
  • Chronic peritoneal inflammation (e.g., Mediterranean familial fever)
  • Secondary/paraoccupational exposure in women: Laundering contaminated work clothing, physical contact with exposed family members, and household dust are primary exposure routes for many female patients

Occupational Exposure Groups

Workers at historically elevated peritoneal mesothelioma risk include asbestos miners and millers, insulation workers, shipyard workers, pipe fitters, boilermakers, and construction tradespeople exposed to asbestos-containing products. Asbestos fibers have also been found in the omentum of patients whose only documented exposure was secondary or environmental.[25] See the corporate concealment page for historical context on industry knowledge of asbestos risks.

Patients diagnosed with peritoneal mesothelioma have the same legal rights to compensation as those with pleural mesothelioma, though the legal pathway may present additional complexities due to the lower asbestos attribution rate.


⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Asbestos Trust Funds

More than 60 asbestos bankruptcy trusts hold an estimated $25–30 billion available for qualified claimants.[26] Individual trust payments range from $7,000 to $1.2 million per trust, with patients typically filing claims against multiple trusts.[27] The average total recovery across all trust funds is approximately $300,000–$400,000.[28] Peritoneal mesothelioma patients are eligible for trust fund claims on the same basis as pleural mesothelioma patients. For more information on filing, see asbestos trust funds and trust fund claims.

Lawsuits and Verdicts

Average mesothelioma lawsuit settlements fall between $1 million and $1.4 million.[26] Trial verdicts average approximately $2.4 million, with notable cases far exceeding these averages — a 2022 California jury awarded $53.3 million to a mesothelioma patient, and a 2025 Boston jury awarded $8 million to a woman whose disease was linked to talcum powder use.[29] Patients may pursue both trust fund claims and personal injury lawsuits simultaneously to maximize total compensation. See the claims process and statute of limitations pages for state-specific filing deadlines.

Peritoneal mesothelioma cases present distinctive legal challenges. Defense attorneys may argue that the lower asbestos attribution rate (60–80% versus 96% for pleural) weakens the causal link. Female plaintiffs with secondary exposure claims, patients with BAP1 mutations, and patients with shorter latency periods all face potential challenges to causation arguments. Experienced mesothelioma attorneys address these challenges through expert medical testimony, occupational and residential exposure history, epidemiological studies of dose-response relationships, and — where relevant — fiber burden analysis and genetic testing evidence.[26][30]

Get Help

Free, Confidential Case Evaluation

Call (866) 222-9990 or visit dandell.com/contact-us

No upfront fees • Experienced representation • National practice

Frequently Asked Questions

What is peritoneal mesothelioma?

Peritoneal mesothelioma is a cancer of the peritoneum — the thin membrane lining the abdominal cavity and covering the abdominal organs. It is caused primarily by asbestos fiber ingestion or fiber translocation from the pleural space and accounts for approximately 7–30% of all mesothelioma diagnoses. Approximately 800 new cases are diagnosed in the United States each year.[1][4]

How is peritoneal mesothelioma different from pleural mesothelioma?

Peritoneal mesothelioma develops in the abdominal lining rather than the lung lining, presents with abdominal symptoms (ascites, bloating, pain) rather than chest symptoms, has a near-equal male-to-female ratio (versus 4:1 male predominance in pleural disease), and is more amenable to surgical treatment via CRS/HIPEC. When optimally treated, peritoneal mesothelioma has a substantially better prognosis — 47% 5-year survival with CRS/HIPEC versus approximately 5% for pleural mesothelioma.[2][12]

What is HIPEC and who is eligible?

HIPEC (hyperthermic intraperitoneal chemotherapy) is a treatment in which heated chemotherapy is circulated directly inside the abdominal cavity immediately after cytoreductive surgery removes all visible tumor. The heat enhances chemotherapy penetration and helps kill microscopic residual cancer cells.[17] Candidates generally have a PCI score below 20, epithelioid or biphasic histology, adequate performance status, and preserved small bowel anatomy. All potentially eligible patients should be evaluated by a peritoneal surface oncology specialist at a high-volume center.[9]

What is the survival rate for peritoneal mesothelioma?

Survival varies significantly by treatment. Without treatment, median survival is approximately 6 months. With systemic chemotherapy alone, median survival is approximately 12 months. With CRS/HIPEC, median survival is 34–92 months (averaging around 53 months in the largest multi-institutional study), and 5-year survival rates of 41–59% have been reported at major centers.[3][11] Patients with epithelioid histology, low PCI scores, and female sex have the best outcomes.[1]

Can you get compensation for peritoneal mesothelioma without a documented asbestos exposure?

Yes. Even when a patient cannot identify a specific occupational exposure, compensation may still be recoverable. Secondary (paraoccupational) exposure — such as from laundering contaminated clothing or household asbestos dust — is a recognized legal basis for claims. BAP1 germline mutations combined with any level of asbestos exposure can establish causation. Approximately 20–40% of peritoneal mesothelioma cases lack documented occupational exposure, and experienced mesothelioma attorneys are accustomed to building these cases.[26][28] Contact a qualified mesothelioma attorney to evaluate your specific circumstances.


See Also

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 Diagnosis and management of patients with malignant peritoneal mesothelioma, PMC4754312, Journal of Gastrointestinal Oncology
  2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma, PMC5674249, Translational Lung Cancer Research
  3. ↑ 3.0 3.1 3.2 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-institutional Experience, Journal of Clinical Oncology, Yan et al. 2009 (401 patients, 29 centers)
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States, PMC9818958, Cancers (SEER 2000–2018 analysis)
  5. ↑ Mesothelioma Overview and Asbestos Causation, Danziger & De Llano, Mesothelioma Attorneys
  6. ↑ 6.0 6.1 Peritoneal Mesothelioma: Survival and Prognosis, Mesothelioma.net
  7. ↑ Imaging, pathological and molecular detection of malignant peritoneal mesothelioma: a case description, PMC11652017, Frontiers in Oncology
  8. ↑ 8.0 8.1 Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma, Scientific Reports, 2020
  9. ↑ 9.0 9.1 Peritoneal Mesothelioma Treatment and HIPEC, Danziger & De Llano, Mesothelioma Attorneys
  10. ↑ Peritoneal Mesothelioma Overview, Mesothelioma Lawyer Center
  11. ↑ 11.0 11.1 Long-term Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma, Sugarbaker PH, Scientific Archives, 2022
  12. ↑ 12.0 12.1 Mesothelioma Treatment Options, Danziger & De Llano, Mesothelioma Attorneys
  13. ↑ 13.0 13.1 Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma, PMC6436227, Annals of Oncology
  14. ↑ Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma, European Journal of Cancer, 2025
  15. ↑ Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature, PMC11291227, Frontiers in Oncology, 2024
  16. ↑ NCT05041062 — Perioperative Nivolumab and Ipilimumab for Peritoneal Mesothelioma, National Cancer Institute Clinical Trials
  17. ↑ 17.0 17.1 HIPEC Treatment for Peritoneal Mesothelioma, Mesothelioma Lawyer Center
  18. ↑ Neoadjuvant PIPAC for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma, American Journal of Case Reports, 2025
  19. ↑ The emergence of pressurized intraperitoneal aerosol chemotherapy as a palliative treatment option for patients with diffuse peritoneal metastases, PMC8100694, Journal of Peritoneal and Retroperitoneal Diseases
  20. ↑ Clinical Characteristics and Outcomes of Patients with Well-Differentiated Papillary Mesothelioma, PMC11466981, Annals of Surgical Oncology, 2024
  21. ↑ Mesothelioma Prognosis and Survival Factors, Danziger & De Llano, Mesothelioma Attorneys
  22. ↑ Update on the management of malignant peritoneal mesothelioma, PMC6204413, Annals of Surgical Oncology
  23. ↑ Report on the Expert Panel on Health Effects of Asbestos and Synthetic Vitreous Fibers, ATSDR / CDC
  24. ↑ Asbestos Exposure and Latency Period, Danziger & De Llano, Mesothelioma Attorneys
  25. ↑ Asbestos Ingestion and Peritoneal Mesothelioma, Mesothelioma.net
  26. ↑ 26.0 26.1 26.2 26.3 Mesothelioma Compensation and Legal Rights, Danziger & De Llano, Mesothelioma Attorneys
  27. ↑ Asbestos Trust Fund Claims for Mesothelioma, Mesothelioma Lawyer Center
  28. ↑ 28.0 28.1 Asbestos Trust Fund Compensation Guide, MesotheliomaAttorney.com
  29. ↑ Mesothelioma Lawsuit Settlements and Verdicts, Mesothelioma Lawyer Center
  30. ↑ Peritoneal Mesothelioma Legal Rights, MesotheliomaAttorney.com
Retrieved from "https://wikimesothelioma.com/w/index.php?title=Peritoneal_Mesothelioma&oldid=2063"